ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc Resubmission of sNDA for Pimavanserin for the Treatment of ADP Call Transcript

Dec 20, 2021 / 09:30PM GMT
Release Date Price: $27.09 (+5.16%)
Operator

Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals conference call. My name is Latif, and I will be your coordinator for today. (Operator Instructions)

I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.

Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

Thank you, Latif. Good afternoon, and thank you for joining us. On today's call, Steve Davis, our Chief Executive Officer, will discuss our plan to resubmit the supplemental NDA for pimavanserin. After which, Dr. Serge Stankovic, our President, will provide further detail on our resubmission strategy. Then, following Steve's closing remarks, we will conduct a question-and-answer session. Mark Schneyer, our Chief Financial Officer; and Brendan Teehan, our Chief Operating Officer and Head of Commercial, will also be available for questions and answers.

I would also like to point out that we're using supplement slides, which are available on the Events and Presentations section of our website.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot